. Author manuscript; available in PMC: 2011 Sep 1.

Published in final edited form as: Pharmacogenet Genomics. 2010 Sep;20(9):532–536. doi: 10.1097/FPC.0b013e32833d3acb

Table 1.

Characteristics of Cases and Controls

Characteristic	ACEi exposed controls (397)	ACEi angioedema cases (169)
Blacks : Whites	179 : 218	87 : 82
Male : Female	200 : 197	73 : 96
Age (years)	57.4 ± 11.4	57.3 ± 14.1
Median ACE inhibitor exposure months (n)	42 (299)	5 (92)^*
Diabetic : Non-diabetic	147 : 247	54 : 112
Smoker : Non-smoker	102 : 293	49 : 116
Seasonal allergies (yes:no)	184:213	97:51^*
APP activity (pmoles/ml/min)	216.88 ± 161.07 (n=387)	220.60 ± 162.19 (n=149)
DPPIV activity (nmoles/ml/min)	30.45 ± 8.74 (n=373)	28.24 ± 10.88 (n=144)^†

Data presented as means ± standard deviations.

P<0.001

^†

P<0.05 versus control